370 related articles for article (PubMed ID: 18375647)
21. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
Wason JM; Trippa L
Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
[TBL] [Abstract][Full Text] [Related]
22. An optimal three-stage design for phase II clinical trials.
Ensign LG; Gehan EA; Kamen DS; Thall PF
Stat Med; 1994 Sep; 13(17):1727-36. PubMed ID: 7997706
[TBL] [Abstract][Full Text] [Related]
23. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
24. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
Cellamare M; Sambucini V
Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
[TBL] [Abstract][Full Text] [Related]
25. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
Zhou H; Chen C; Sun L; Yuan Y
Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
[TBL] [Abstract][Full Text] [Related]
26. Optimal two-stage designs for single arm phase II cancer trials.
Shuster J
J Biopharm Stat; 2002 Feb; 12(1):39-51. PubMed ID: 12146719
[TBL] [Abstract][Full Text] [Related]
27. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Thall PF; Simon RM; Estey EH
J Clin Oncol; 1996 Jan; 14(1):296-303. PubMed ID: 8558211
[TBL] [Abstract][Full Text] [Related]
28. Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method.
Chen N; Lee JJ
Contemp Clin Trials; 2013 May; 35(1):170-8. PubMed ID: 23545075
[TBL] [Abstract][Full Text] [Related]
29. Bayesian designs with frequentist and Bayesian error rate considerations.
Wang YG; Leung DH; Li M; Tan SB
Stat Methods Med Res; 2005 Oct; 14(5):445-56. PubMed ID: 16248347
[TBL] [Abstract][Full Text] [Related]
30. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
31. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
Kaizer A; Zabor E; Nie L; Hobbs B
PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
[TBL] [Abstract][Full Text] [Related]
32. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Zhou H; Lee JJ; Yuan Y
Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
[TBL] [Abstract][Full Text] [Related]
33. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
Guo B; Li Y
BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
[TBL] [Abstract][Full Text] [Related]
34. Interpreting a Bayesian phase II futility clinical trial.
Beall J; Cassarly C; Martin R
Trials; 2022 Nov; 23(1):953. PubMed ID: 36414953
[TBL] [Abstract][Full Text] [Related]
35. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
[TBL] [Abstract][Full Text] [Related]
36. A Bayesian predictive two-stage design for phase II clinical trials.
Sambucini V
Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
[TBL] [Abstract][Full Text] [Related]
37. Controlled multi-arm platform design using predictive probability.
Hobbs BP; Chen N; Lee JJ
Stat Methods Med Res; 2018 Jan; 27(1):65-78. PubMed ID: 26763586
[TBL] [Abstract][Full Text] [Related]
38. Bayesian two-stage design for phase II oncology trials with binary endpoint.
Chen L; Pan J; Wu Y; Wang J; Chen F; Zhao J; Chen P
Stat Med; 2022 May; 41(12):2291-2301. PubMed ID: 35178729
[TBL] [Abstract][Full Text] [Related]
39. Design of Phase II cancer trials evaluating survival probabilities.
Case LD; Morgan TM
BMC Med Res Methodol; 2003 Apr; 3():6. PubMed ID: 12697051
[TBL] [Abstract][Full Text] [Related]
40. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Taylor DJ; Grobler A; Abdool Karim SS
Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
